- Market Capitalization, $K 54,608
- Shares Outstanding, K 37,661
- Annual Sales, $ 1,260 K
- Annual Income, $ -98,590 K
- 60-Month Beta 1.02
- Price/Sales 42.14
- Price/Cash Flow N/A
- Price/Book 0.28
|Period||Period Low||Period High||Performance|
| || |
+0.0600 (+4.48%)since 11/04/22
| || |
-0.3700 (-20.90%)since 09/02/22
| || |
-9.1000 (-86.67%)since 12/03/21
Biohaven Ltd. (BHVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regeneron (REGN) gets a positive recommendation from CHMP for the label expansion of its oncology drug for treating adult patients with recurrent or metastatic cervical cancer.
Novartis (NVS) radioligand therapy Pluvicto gets positive recommendation by the CHMP for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer.
Gilead's (GILD) efforts to expand Trodelvy's label progress, as the FDA accepts sBLA for the same and grants Priority Review.
Cytokinetics (CYTK) plans to continue the COURAGE-ALS study on reldesemtiv in patients with amyotrophic lateral sclerosis following DMC recommendation.
Rigel (RIGL) decides to back out from the label expansion of fostamatinib for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA) following the FDA???s review.
Gilead (GILD) is having a good run despite the volatility on a string of positive updates.
VIR shares gain following a multi-year contract from BARDA for the development of influenza and other emerging infectious disease or medical countermeasure candidates.
Provention (PRVB) collaborates with Sanofi for the commercialization of lead investigational drug candidate teplizumab.
Amylyx (AMLX) obtains the FDA's approval for its oral, fixed-dose combination therapy for treating adults with amyotrophic lateral sclerosis (ALS) after a few roadblocks.
|Bolt Biotherapeutics Inc|
|Invesco Nasdaq Biotechnology ETF|
|Dimensional U.S. Core Equity 2 ETF|
|S&P Total US Stock Market Ishares Core ETF|
|Nasdaq Biotechnology Ishares ETF|
|Micro-Cap Ishares ETF|
|3rd Resistance Point||1.5633|
|2nd Resistance Point||1.5167|
|1st Resistance Point||1.4833|
|1st Support Level||1.4033|
|2nd Support Level||1.3567|
|3rd Support Level||1.3233|